Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. The trial, which targeted pain caused by a pinched nerve in the spine, showed no significant difference in pain reduction compared to a placebo. The company also announced plans to proceed with a Phase 3 trial for suzetrigine, a decision that has left some analysts questioning the rationale. One commentator stated on X “Vertex often gets the benefit of the doubt given its track record, but damn, this one is tough to reconcile.” The company’s announcements come mere days after insider transactions have been reported.
Following this news, shares of Vertex fell 12% in morning trading on the same day.